BMEA
Biomea Fusion IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$109.17M
P/E Ratio
—
EPS
$-1.18
Beta
-0.27
52W High
$3.08
52W Low
$0.87
50-Day MA
$1.30
200-Day MA
$1.53
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Biomea Fusion Inc
Biomea Fusion, Inc., a biopharmaceutical company, is focused on the discovery, development and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company is headquartered in Redwood City, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-79.90M |
| Operating Margin | 0.00% |
| Return on Equity | -152.40% |
| Return on Assets | -73.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.41 |
| Price-to-Book | 3.75 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -3.75 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $72.30M |
| Float | $67.44M |
| % Insiders | 7.23% |
| % Institutions | 37.35% |
Analyst Ratings
Consensus ($7.17 target)
1
Strong Buy5
Buy1
Strong SellData last updated: 4/7/2026